The drugmaker and its owners agreed to pay $270 million to settle the lawsuit brought against them in Oklahoma. The majority of the money will fund a national opioid addiction center in the state.
The deal allows Purdue Pharma to sidestep a May trial, the first trial scheduled among the opioid cases. The trial could have exposed the company to damaging testimony and a jury verdict. It also allows Purdue Pharma, which was considering bankruptcy, to avoid filing for bankruptcy for now.
Purdue Pharma now can focus on the rest of the lawsuits filed by more than 35 states and hundreds of municipalities.
The Oklahoma deal could speed up those settlement talks, Elizabeth Burch, a law professor at the University of Georgia, told the WSJ: “It’s got to set off a feeding frenzy. There’s blood in the water now.”
The next trials are set to begin in Ohio in the fall, also the likely time for more settlements or even a bankruptcy filing, according to the report.
More articles on pharmacy:
10 hospitals seeking pharmacy leadership
Patent protection clause is latest stumbling block for revised NAFTA
Dr. Reddy’s legal win expected to lower cost of opioid addiction treatment
